Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0023 • ACR Convergence 2021
Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
Matthew Wright¹, Dana Goin², Mette Smed³, J Lee Nelson⁴, Nicholas Jewell⁵, Jorn Olsen⁶, Merete Hetland⁷, Vibeke Zoffmann³ and Damini Jawaheer⁸, ¹UCSF Benioff Children's Hospital Oakland, Oakland, CA, ²University of California San Francisco, San Francisco, CA, ³Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, ⁵University of California Berkeley, Berkeley, CA, ⁶Aarhus University Hospital, Aarhus, Denmark, ⁷DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁸UCSF Benioff Children's Hospital Oakland / University of California San Francisco, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA), while still an incurable disease, can often improve naturally during pregnancy. The specific mechanism(s) underlying this pregnancy-induced improvement, however, are not…
Abstract Number: 0039 • ACR Convergence 2021
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Joseph Couto¹, Elisea Avalos-Reyes², Amanda McCarthy³, Olga Matlin⁴, Michele Hamburger⁵, Gerard Maher⁶ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Irving, TX, ³CVS Health, Greensboro, GA, ⁴CVS Health, Northbrook, IL, ⁵Frances Hamburger Institute, Hauppauge, NY, ⁶Frances Hamburger Institute, Hauppaugue, NY
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
Abstract Number: 0200 • ACR Convergence 2021
In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
Marloes Verstappen, Xanthe Matthijssen and Annette H.M van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…
Abstract Number: 0278 • ACR Convergence 2021
Higher Prevalence of Eccentric Hypertrophy in Rheumatoid Arthritis Patients: A Case-Control Study
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Natalia Guajardo-Jauregui, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Alan De Leon-Yañez and Catalina Andrade-Vazquez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of cardiovascular diseases and a strong association with abnormalities in the left ventricular (LV) geometry.…
Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Misako Higashida-Konishi¹, Keisuke Izumi², Tatsuya Shimada³, Satoshi Hama⁴, Mitsuhiro Akiyama⁵, Hisaji Oshima⁴ and Yutaka Okano⁶, ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, tokyo, Japan, ⁵Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center/ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Palo Alto, CA, ⁶Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…
Abstract Number: 0515 • ACR Convergence 2021
The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
Abstract Number: 0579 • ACR Convergence 2021
Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent
Yinzhu Jin¹, Joan Landon¹, Whitney Krueger², Alexander Liede² and Seoyoung Kim³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²AbbVie Global Epidemiology, Chicago, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patient characteristics including serostatus, body mass index (BMI), and smoking are considered to be associated with their response to disease-modifying anti-rheumatic drugs (DMARD) treatment…
Abstract Number: 0608 • ACR Convergence 2021
Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients
Valerie Umaefulam¹, Terri-Lynn Fox¹, Glen Hazlewood¹, Nick Bansback², Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patient decision aids (PtDA) can enable shared decision-making between patients and healthcare providers. We have previously developed a PtDA for first-line methotrexate-based treatment options…
Abstract Number: 0787 • ACR Convergence 2021
Association of Hemoglobin Levels and Radiographic Progression in the BRASS Registry
Nancy Shadick¹, Owen Hagino², Amy Praestgaard³, Stefano Fiore², Michael Weinblatt⁴ and Gerd Burmester⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Sanofi, Bridgewater, NJ, ³Sanofi, Cambridge, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: To evaluate baseline hemoglobin (Hb) and radiographic progression over time for patients in the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS) registry.Methods:…
Abstract Number: 0803 • ACR Convergence 2021
Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
William Arnold¹, Erin Arnold¹, David Sikes², Gary Crump³, Kathleen Thomas⁴ and andrew johnson⁵, ¹Arnold Arthritis and Rheumatology, Wilmette, IL, ²Florida Medical Clinic, Wesley Chapel, FL, ³Rheumatology Associates, Louisville, KY, ⁴Community Health Network, Noblesville, IN, ⁵PopMed Solutions, Boyds, MD
Background/Purpose: The RAPP quality improvement project is a voluntary consortium of practicing rheumatologists founded in 2013 by Timothy Harrington MD, MACR. The primary focus is…
Abstract Number: 0821 • ACR Convergence 2021
Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
Rieke Alten¹, Xavier Mariette², Mauro Galeazzi³, Melanie Chartier⁴, Christiane Rauch⁵, Yedid Elbez⁶ and Karissa Lozenski⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³University of Siena, Siena, Italy, ⁴Bristol Myers Squibb, Rueil-Malmaison, France, ⁵Bristol Myers Squibb, Munich, Germany, ⁶Deepscover, Puteaux, France, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Identifying factors associated with treatment response and remission in patients with RA may assist with therapeutic decision-making. An international observational study evaluated efficacy and…
Abstract Number: 0839 • ACR Convergence 2021
Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort
Lisa Christ¹, Seraphina Kissling², Ruediger B. Mueller³, Axel Finckh⁴, Benjamin Fisher⁵, Britta Maurer¹, Burkhard Moeller⁶ and Florian Kollert¹, ¹Department of Rheumatology and Immunology, University Hospital (Inselspital) and University of Bern, Bern, Switzerland, ²Statistics and Data Management Group, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, ³Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ⁴University Hospital of Geneva, Geneve - Vesenaz, Switzerland, ⁵Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: The variety of treatment options in RA contrasts with a lack of personalized medicine. The presence of concomitant SjS might be associated with differerences…
Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Andrea Rubbert-Roth¹, Nicolas Vuilleumier², Burkhard Ludewig³, Kristin Schmiedeberg⁴, Yella Rottlaender⁴, Ian Pirker⁵ and Johannes VonKempis⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Departement Diagnostique, University of Geneva, Switzerland, Geneva, Switzerland, ³Institute of Immunobiology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁶Division of Rheumatology and Immunology, St. Gallen, Switzerland
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
Abstract Number: 1071 • ACR Convergence 2021
Experiences Using Wearable Technology by Persons with Rheumatoid Arthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Analysis
Jenny Leese¹, Siyi Zhu², Anne Townsend³, Catherine L. Backman¹, Laura Nimmon¹ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²Sichuan University, Chengdu, China (People's Republic), ³Lancaster University, Lancaster, United Kingdom
Background/Purpose: Using wearables to self-monitor physical activity is a promising approach to support self-management among persons with arthritis. Evidence indicates, from perspectives of persons with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].